Eli Lilly Acquires Centessa Pharmaceuticals for $6.3B in Sleep Disorder Focus

Eli Lilly's $6.3 billion purchase of Centessa Pharmaceuticals marks a strategic move into sleep disorder treatments, with Centessa's lead drug in Phase 2 trials. This deal underscores Lilly’s ambition to expand its portfolio amidst international pricing pressures driven by U.S. policies. Market implications suggest increased competition and innovation in sleep disorder therapies are likely.